To verify the potential therapeutic effect of SSKE on CKD by improving intestinal epithelial barrier injury, we examined the expression levels of Occludin, Claudin-1, and ZO-1 using immunohistochemistry (IHC). Here, CLDN1 is linked to chronic kidney disease.